Wellington Management Group LLP Raises Position in Artivion, Inc. (NYSE:AORT)

Wellington Management Group LLP raised its holdings in shares of Artivion, Inc. (NYSE:AORT) by 0.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,660,081 shares of the company’s stock after acquiring an additional 3,817 shares during the period. Wellington Management Group LLP’s holdings in Artivion were worth $47,462,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Quarry LP raised its position in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after buying an additional 820 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after purchasing an additional 786 shares in the last quarter. R Squared Ltd bought a new stake in Artivion during the fourth quarter worth about $39,000. Arcadia Investment Management Corp MI purchased a new position in shares of Artivion in the 4th quarter worth about $43,000. Finally, Venturi Wealth Management LLC bought a new position in shares of Artivion during the 4th quarter valued at about $78,000. 86.37% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Lance A. Berry sold 3,259 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $89,003.29. Following the completion of the sale, the chief financial officer now directly owns 75,805 shares of the company’s stock, valued at approximately $2,070,234.55. This trade represents a 4.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO James P. Mackin sold 42,156 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the transaction, the chief executive officer now owns 663,882 shares in the company, valued at $18,130,617.42. This represents a 5.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 90,799 shares of company stock worth $2,356,223. 8.10% of the stock is currently owned by company insiders.

Artivion Stock Down 3.7 %

Shares of Artivion stock opened at $23.24 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion, Inc. has a 52-week low of $19.36 and a 52-week high of $32.33. The company’s 50 day moving average price is $26.93 and its 200-day moving average price is $27.61. The stock has a market capitalization of $977.20 million, a price-to-earnings ratio of -1,162.00 and a beta of 1.65.

Artivion (NYSE:AORT) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The firm had revenue of $97.31 million during the quarter, compared to analysts’ expectations of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Equities research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Needham & Company LLC cut their target price on Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Finally, Stifel Nicolaus lowered their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.